Pacira | PCRX - Selling And Administration Expenses


Pacira reported $83.88M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Astellas Pharma JPY 234.7B 12.92B Mar/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Cara Therapeutics USD 2.09M 96K Mar/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
J&J USD 6.42B 381M Jun/2026
Ligand Pharmaceuticals USD 20.84M 4.19M Mar/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novo Nordisk DKK 13.22B 4.22B Mar/2026
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 83.88M 7.99M Mar/2026
Perrigo USD 267.3M 11.4M Mar/2026
Pfizer USD 3.41B 496M Jun/2026
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
Teva Pharmaceutical Industries USD 1.03B 34M Jun/2026
Xeris Pharmaceuticals USD 53.14M 10.51M Mar/2026
Zoetis USD 588M 31M Mar/2026